BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and invest...
Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
BioCentury’s analysis of the technologies behind last year’s biotech series A raisers sees progress in nanoparticles, CAR cell therapies, degraders and antibody-drug conjugates. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the trends spotted in 2024’s crop of more than 150 series A rounds — from top therapeutic areas and modalities to the leading investors funding the innovation.The editors turn to Washington for takeaways from BioCentury’s “exit interview” with Patrizia Cavazzoni, the recently departed director of FDA’s Center for Drug Evaluation and Research, and checks in on FDA and NIH’s turbulent transition under Trump 2.0.Finally, the podcast team previews BioCentury’s upcoming fourth East-West Summit, which will focus on globalizing Asia innovation and the red-hot “Newco Model” in Singapore March 3-5, and the twenty-fifth Bio€quity Europe, which will be held in Belgium in May. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/65483700:01 - Sponsor Message: ICON Biotech01:57 - Series As: Trends in Innovation12:18 - BioCentury Conferences Preview18:45 - Insights from FDA's Cavazzoni21:58 - Turbulence at FDA, NIHTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
33:09
Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
With political uncertainty overshadowing market sentiment going into 2025, BioCentury’s editorial team assesses the bull and bear arguments for biotech in the New Year on the BioCentury This Week podcast’s Public Markets Preview. Will continued uncertainty drive biotech sentiment in the coming months, or will the bear arguments fail to manifest, stymied by M&A and other positive factors?In the second part of the 2025 Preview, BioCentury’s editors highlight some of the key catalysts in bispecifics, immunology and inflammatory (I&I), new modalities, and neurology and obesity they are watching in the year ahead. Finally, the editors discuss how VC firms focused on AI-driven drug development are thinking about the resources and strategies needed to turn promise into reality. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/65477200:01 - Sponsor Message: ICON Biotech02:33 - Market Uncertainty12:50 - Biotech Catalysts 21:12 - Obesity22:57 - Neurology28:54 - AI: VC PerspectivesTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
36:21
Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
Sunshine and a stream of deals brightened the mood at this year’s J.P. Morgan Healthcare Conference, offering a pleasant counterpoint to continued pessimism over the state of the capital markets. On the latest BioCentury This Week podcast, BioCentury’s editors deliver their takeaways from biotech’s annual kick-off event from megarounds and Asian newcos to the new state of M&A and pending change at FDA.View full story: https://www.biocentury.com/article/65472300:00 - Introduction01:52 - Market Sentiments and Deal Expectations04:42 - Cross-Border Deals and Asia's Growing Influence07:12 - Neurology and Innovation in Biotech14:44 - VC Trends and Megarounds20:00 - Upcoming East West SingaporeTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
22:21
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
J&J’s $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference’s pre-pandemic days. On the latest BioCentury This Week podcast, BioCentury's editors discuss the takeout of Intra-cellular, the third 11-digit neuro M&A in the past 13 months, as well as M&A involving Idrx and GSK, and Scorpion Therapeutics and Eli Lilly. Turning to Washington, the team explores what’s behind BIO CEO John Crowley’s visit to Mar-a-Lago to meet with President-elect Donald Trump, impending changes at FDA under Trump 2.0 and key takeaways from Rep. Jake Auchincloss appearance on BCTW’s sister podcast, The BioCentury Show. The team also breaks down the key trends in the past year in FDA approvals. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/65469400:01 - Sponsor Message: ICON Biotech02:38 - JPM Deal Buzz11:20 - Washington Update16:08 - Rep. Auchincloss’ Take on Biopharma 21:01 - FDA Regulatory DecisionsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
--------
27:29
Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure
Can biotech break free of the macro factors that have buffeted the industry of late? On the first BioCentury This Week podcast of 2025, BioCentury’s editors offer their predictions for the New Year and — exploring the themes from Simone Fishburn’s latest Letter from the Editor — ask whether biotech can overcome the financing environment, policy concerns and geopolitical tension that have been hammering the industry to deliver on the meaningful strides companies have been taking to deliver innovations to patients.Plus, Washington Editor Steve Usdin discusses what U.S. policymakers need to do now in the wake of a year’s worth of wrangling over the Biosecure Act, and Executive Editor Selina Koch breaks down readouts from Neumora on its KOR antagonist navacaprant to treat major depressive disorder and Axsome Therapeutics for its AXS-05 to treat agitation in Alzheimer’s patients. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/654620 00:01 - Sponsor Message: ICON Biotech01:51 - Biotech's Repeating Challenges10:52 - Biotech in the New Year23:07 - Beyond Biosecure28:10 - Neurology ReadoutsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Colombia